Emerging drugs for colorectal cancer.
作者： David R Fogelman , Scott Kopetz , Cathy Eng
DOI: 10.1517/14728210802544575
关键词:
摘要: Background: The past 5 years have shown major advances in the treatment of colorectal cancer. Our understanding existing drugs, such as oxaliplatin and irinotecan, has become more refined. incorporation newer drugs bevacizumab cetuximab expanded options well. Objective: goals are to review evidence for currently approved with particular attention most recent studies highlighting ideal conditions each. In addition, we discuss current areas investigation – particularly, specific pathway inhibitors that relevant Methods: We used literature well abstracts oral presentations from ASCO AACR meetings. Results/conclusion: report thinking on use present promising novel now being developed
sci-hub.se 参考文章(77)
Scott Kopetz, Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic Gastrointestinal cancer research : GCR. ,vol. 1, ,(2007)
Reversible posterior leukoencephalopathy syndrome and bevacizumab. The New England Journal of Medicine. ,vol. 354, pp. 980- ,(2006) , 10.1056/NEJMC052954
H M Pinedo, G F Peters, Fluorouracil: biochemistry and pharmacology. Journal of Clinical Oncology. ,vol. 6, pp. 1653- 1664 ,(1988) , 10.1200/JCO.1988.6.10.1653
Robbert J. van Alphen, Alex Sparreboom, Kees Nooter, Ron H. J. Mathijssen, Walter J. Loos, Gerrit Stoter, Jaap Verweij, Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clinical Cancer Research. ,vol. 7, pp. 2182- 2194 ,(2001)
F. Loupakis, L. Pollina, I. Stasi, G. Masi, N. Funel, M. Scartozzi, I. Petrini, D. Santini, S. Cascinu, A. Falcone, Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment Journal of Clinical Oncology. ,vol. 26, pp. 4003- 4003 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4003
M A Poon, M J O'Connell, C G Moertel, H S Wieand, S A Cullinan, L K Everson, J E Krook, J A Mailliard, J A Laurie, L K Tschetter, Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. Journal of Clinical Oncology. ,vol. 7, pp. 1407- 1418 ,(1989) , 10.1200/JCO.1989.7.10.1407
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Journal of Clinical Oncology. ,vol. 22, pp. 3766- 3775 ,(2004) , 10.1200/JCO.2004.03.104
Paulo M. Hoff, Rafat Ansari, Gerald Batist, John Cox, Walter Kocha, Mario Kuperminc, Jean Maroun, David Walde, Charles Weaver, Evelyn Harrison, Hans U. Burger, Bruno Osterwalder, Alfred O. Wong, Ralf Wong, Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study Journal of Clinical Oncology. ,vol. 19, pp. 2282- 2292 ,(2001) , 10.1200/JCO.2001.19.8.2282
A de Gramont, J F Bosset, C Milan, P Rougier, O Bouché, P L Etienne, F Morvan, C Louvet, T Guillot, E François, L Bedenne, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. Journal of Clinical Oncology. ,vol. 15, pp. 808- 815 ,(1997) , 10.1200/JCO.1997.15.2.808
Shelly R. Calcagno, Shuhua Li, Migdalisel Colon, Pamela A. Kreinest, E. Aubrey Thompson, Alan P. Fields, Nicole R. Murray, Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. International Journal of Cancer. ,vol. 122, pp. 2462- 2470 ,(2008) , 10.1002/IJC.23383